Enzymlogic receives the SME Instrument Phase I grant from the Horizon 2020 program
Jul, 15th 2019
The KINETICfinder® platfom developed by Enzymlogic has received recognition from the European Commission, and funding from the SME Instrument project Phase 1 within the Horizon 2020 Research and Innovation Framework Programme.
The KINETICfinder® platfom developed by Enzymlogic has received recognition from the European Commission, and funding from the SME Instrument project Phase 1 within the Horizon 2020 Research and Innovation Framework Programme. SME Instrument is a highly competitive tool for breakthrough innovation projects with a market-creating potential as part of the Enhanced European Innovation Council (EIC) pilot.
The Enhanced EIC pilot funds high-potential, high-risk innovation developed by SMEs through the EIC Accelerator Pilot. The EIC Accelerator Pilot offers Europe's brightest and boldest entrepreneurs the chance to step forward and request funding for breakthrough ideas with the potential to create entirely new markets or revolutionise existing ones.
Our innovative platform enables drug kinetic analyses in a massive way and at affordable cost. Carrying out ENZYMLOGIC kinetic analysis in initial discovery phases, when thousands of drugs are under scrutiny, allows pharma companies to preselect the drugs with the greatest possibilities to reach the market, avoiding the cumulative costs associated with the development of inefficient drugs.
Enzymlogic has been one of the 283 companies from 31 countries selected in the latest call of Phase 1 of SME Instrument. Enterprises must meet the highest expectations in order to access SME Instrument funding, and demonstrate talent, differentiation and chances of success. Only 8% of the 3299 proposals recieved by the European Commission have been selected for funding.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867659.